Virtual medical scribing software has revolutionized patient care and made documentation more efficient in the healthcare industry. When selecting virtual medical scribing software, looking for ...

Experts Publish Consensus on CT for Prosthetic Heart Valve Assessment The consensus document was jointly published today in Radiology: Cardiothoracic Imaging, a journal of the Radiological Society of ...

1Elevan Biopharmaceuticals has officially announced its relocation from California to Fishers, Indiana, establishing its new headquarters in the Fishers Life Sciences and Innovation Park. The move ...

Experts from multiple medical societies have published a consensus document to provide guidance on how best to use cardiac CT for prosthetic heart valve assessment. The consensus document was jointly ...

Partnership Combines VERAXA’s Proprietary ADC Technology with OmniAb’s Antibody Discovery Technology for Novel Therapies Targeting Solid Tumors.

The launch marks a significant step in Seed’s evolution from a DTC disruptor to a leading omnichannel brand, amplifying its strategy to make clinically validated microbiome science accessible wherever ...

Setting the Scene: My Tangled Hair Affair Truth bomb right off the bat: my hair was a stubborn mule. For years, I faced mornings wrestling with locks that behaved like defiant teenagers refusing ...

The study “Evaluating a cutting‑edge augmented reality‑supported navigation system for spinal instrumentation”1 led by Prof. Dr. med. Bernhard Meyer, evaluates the efficiency, accuracy, and ...

The Phase 2a study EXIST (EXIdavnemab Synucleinopathy Trial), is a randomized, double-blinded, placebo-controlled study to evaluate the safety and tolerability of exidavnemab and its pharmacokinetic ...

Seed, a microbiome science company, today announced the nationwide retail launch of its clinically validated microbiome innovations at Sprouts Farmers Market. Beginning this week, Seed’s DS-01® Daily ...

The first cohort in the ongoing clinical Phase 2a study EXIST evaluated a lower dose of exidavnemab compared to placebo in patients with Parkinson’s disease. An interim safety review showed that ...

InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard ® Prime carotid stent system for the prevention of stroke, today announced the company has received CE Mark approval under the European Medical ...